Health Care • Biotechnology: Pharmaceutical Preparations
$35.25 ▲ +0.48
(+1.38%)
MKT CAP: $4.16B • VOL: 5.72M
52W L $28 52W H $43
INDV // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.24B | $1.19B | $1.09B |
| YoY Revenue Growth % | +4.3% | +8.7% | — |
| Gross Profit | $994.0M | $957.0M | $480.9M |
| Gross Margin % | 80.2% | 80.6% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $262.0M | $38.0M | -$152.0M |
| Operating Margin % | 21.1% | 3.2% | -13.9% |
| Net Income (GAAP) | $210.0M | $7.0M | -$126.0M |
| EBITDA (Normalized) | $314.8M | $61.2M | -$112.7M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$27.0M | $36.0M | -$300.0M |
| Capital Expenditures (CapEx) | $66.0M | $29.0M | $49.2M |
| Free Cash Flow (FCF) | -$93.0M | $7.0M | -$349.2M |
| FCF Margin % | -7.5% | 0.6% | -31.9% |
| Return on Invested Capital (ROIC %) | 95.0% | 95.0% | -8.7% |
| Cash & Short-Term Equivalents | $195.0M | $319.0M | $251.7M |
| Total Debt (Short + Long Term) | $290.0M | $315.0M | $535.5M |
| Total Stockholders' Equity | -$98.0M | -$337.0M | $1.10B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR INDV.